Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05832463 · ClinicalTrials.gov registry record · NA
Effects of a Novel Supplement on Glycemic Variability Measured by Continuous Glucose Monitoring
A NA study of Healthy, sponsored by dōTERRA International.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT05832463: Completed NA study of Healthy, sponsored by dōTERRA International.
NCT05832463 is a NA study of Healthy that has completed, run by dōTERRA International. The registered enrollment target is 43 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05832463, a NA study of Healthy, has completed, sponsored by dōTERRA International.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a two-cohort, crossover pilot study to determine interstitial glucose levels coincident with the consumption of a novel carbohydrate blocking supplement.
Primary Outcome
This study will monitor the occurrence and frequency of adverse events and safety, both through participant report and blood chemistry/hematology analyses. Dosage for cohort 2 will be determined
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo capsule
- DIETARY_SUPPLEMENT Carbohydrate blocking supplement (CBS)
Study Locations (1)
Utah
- doTERRA International - Pleasant Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2021-05-14 |
| Est. Completion | 2022-07-15 |
| Phase | NA |
What the finished NCT05832463 record still lists
NCT05832463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo capsule is the first listed.
NCT05832463 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05832463 about?
NCT05832463 is a clinical study titled "Effects of a Novel Supplement on Glycemic Variability Measured by Continuous Glucose Monitoring". This is a two-cohort, crossover pilot study to determine interstitial glucose levels coincident with the consumption of a novel carbohydrate blocking supplement.
What is the current status of trial NCT05832463?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2021-05-14. Estimated completion is 2022-07-15.
What conditions does trial NCT05832463 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05832463?
The interventions under investigation include: Placebo capsule (DIETARY_SUPPLEMENT), Carbohydrate blocking supplement (CBS) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05832463?
This trial is sponsored by dōTERRA International, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05832463 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05832463's enrollment target sits among peer trials
43 522nd of 1090 higher than 567 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
RECRUITING · NA
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Medical Illustration Design Characteristic Evaluation
RECRUITING · NA
-
Sodium vs Potassium Education to Improve Vascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI